ReviewGastrointestinal endoscopy clinics of North America2014
The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease.
Review in Gastrointestinal endoscopy clinics of North America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 24 citations in OpenAlex.
- Natural compounds as safe therapeutic options for ulcerative colitis.Inflammopharmacology · 2022Review
- Gastrointestinal neoplasia in patients with inflammatory bowel disease: Opportunities to enhance preventative strategies.JGH open : an open access journal of gastroenterology and hepatology · 2019Article
- Mucosal healing in inflammatory bowel disease: Expanding horizon.Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology · 2019Review
- Colorectal cancer in inflammatory bowel disease: review of the evidence.Techniques in coloproctology · 2019Review
- Dendritic cell profiles in the inflamed colonic mucosa predict the responses to tumor necrosis factor alpha inhibitors in inflammatory bowel disease.Radiology and oncology · 2018Article
- Chemopreventive Effects of Silibinin on Colitis-Associated Tumorigenesis by Inhibiting IL-6/STAT3 Signaling Pathway.Mediators of inflammation · 2018Article
- Prevalence and Anatomic Distribution of Serrated and Adenomatous Lesions in Patients with Inflammatory Bowel Disease.Canadian journal of gastroenterology & hepatology · 2017Article
- Histological inflammation increases the risk of colorectal neoplasia in ulcerative colitis: a systematic review.Intestinal research · 2016Review
- Chemoprophylaxis of precancerous lesions in patients who are at a high risk of developing colorectal cancer (Review).Medicine internationalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
It has been proposed that effective disease control through abrogation of inflammation in IBD may also reduce CRC risk in these individual patients. This article summarizes the potential for medical therapy to reduce the risk of CRC via primary and secondary prevention, and offers practical ways in which a goal of mucosal improvement or healing may be incorporated into clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.